Trial Profile
A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 This trial has been completed in Sweden, UK and Greece (Global End Date: 21 Aug 2019), according to European Clinical Trials Database record.
- 08 Nov 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.